Wilma L. Lingle

15.1k total citations · 3 hit papers
102 papers, 7.4k citations indexed

About

Wilma L. Lingle is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Wilma L. Lingle has authored 102 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 49 papers in Oncology and 26 papers in Cell Biology. Recurrent topics in Wilma L. Lingle's work include HER2/EGFR in Cancer Research (26 papers), Microtubule and mitosis dynamics (23 papers) and Cancer-related Molecular Pathways (14 papers). Wilma L. Lingle is often cited by papers focused on HER2/EGFR in Cancer Research (26 papers), Microtubule and mitosis dynamics (23 papers) and Cancer-related Molecular Pathways (14 papers). Wilma L. Lingle collaborates with scholars based in United States, Italy and China. Wilma L. Lingle's co-authors include Jeffrey L. Salisbury, James N. Ingle, Vera J. Suman, Daniel W. Visscher, Carol Reynolds, Antonino B. D’Assoro, Edith A. Perez, Vivian Negron, W Lütz and Matthew P. Goetz and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Wilma L. Lingle

102 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Benign Breast Disease and the Risk of Breast Cancer

2005 628 citations Lynn C. Hartmann, Wilma L. Lingle et al. profile →
FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt

2009 568 citations Wilma L. Lingle et al. profile →
Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

2005 567 citations Matthew P. Goetz, Vera J. Suman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wilma L. Lingle United States	44	3.6k	3.1k	2.0k	1.7k	1.4k	102	7.4k
Yasuo Miyoshi Japan	52	4.6k 1.3×	3.4k 1.1×	2.3k 1.2×	805 0.5×	1.6k 1.1×	252	9.3k
Khandan Keyomarsi United States	51	6.7k 1.8×	5.5k 1.8×	2.2k 1.1×	1.7k 1.0×	955 0.7×	158	10.7k
Gerald McMahon United States	45	7.0k 1.9×	3.1k 1.0×	2.9k 1.5×	937 0.6×	588 0.4×	77	11.8k
Brion W. Murray United States	33	6.2k 1.7×	2.4k 0.8×	2.3k 1.2×	762 0.5×	398 0.3×	63	9.8k
Göran Landberg Sweden	58	5.6k 1.5×	4.5k 1.4×	3.0k 1.5×	837 0.5×	1.2k 0.8×	211	10.2k
Carol A. Lange United States	53	6.5k 1.8×	3.4k 1.1×	1.7k 0.9×	661 0.4×	3.3k 2.3×	140	10.4k
Andrew S. Kraft United States	55	6.9k 1.9×	3.4k 1.1×	1.1k 0.6×	749 0.4×	517 0.4×	180	10.7k
Atanasio Pandiella Spain	57	6.6k 1.8×	4.9k 1.6×	1.5k 0.8×	771 0.5×	429 0.3×	284	11.6k
Elizabeth A. Musgrove Australia	60	7.4k 2.0×	6.6k 2.1×	3.2k 1.6×	1.1k 0.6×	3.0k 2.1×	144	13.6k
Alain Puisieux France	52	7.4k 2.1×	6.0k 1.9×	3.5k 1.8×	1.0k 0.6×	956 0.7×	182	13.0k

Countries citing papers authored by Wilma L. Lingle

Since Specialization

Citations

This map shows the geographic impact of Wilma L. Lingle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilma L. Lingle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilma L. Lingle more than expected).

Fields of papers citing papers by Wilma L. Lingle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilma L. Lingle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilma L. Lingle. The network helps show where Wilma L. Lingle may publish in the future.

Co-authorship network of co-authors of Wilma L. Lingle

This figure shows the co-authorship network connecting the top 25 collaborators of Wilma L. Lingle. A scholar is included among the top collaborators of Wilma L. Lingle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilma L. Lingle. Wilma L. Lingle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suman, Vera J., Malayannan Subramaniam, Xianglin Wu, et al.. (2014). ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer. BMC Cancer. 14(1). 749–749. 54 indexed citations

Dueck, Amylou C., Monica M. Reinholz, Xochiquetzal J. Geiger, et al.. (2013). Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831. Clinical Cancer Research. 19(20). 5798–5807. 19 indexed citations

Perez, Edith A., Amylou C. Dueck, Ann E. McCullough, et al.. (2013). Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial. Journal of Clinical Oncology. 31(17). 2115–2122. 89 indexed citations

Moreno‐Aspitia, Alvaro, David W. Hillman, Kathleen Tenner, et al.. (2013). Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer. 119(15). 2675–2682. 40 indexed citations

Perez, Edith A., Michael F. Press, Amylou C. Dueck, et al.. (2013). Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Research and Treatment. 138(1). 99–108. 63 indexed citations

Harrington, Sean C., S. John Weroha, Carol Reynolds, et al.. (2012). Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Hormone & IGF Research. 22(3-4). 108–115. 40 indexed citations

Khurana, Ashwani, Peng Liu, Pasquale Mellone, et al.. (2011). HSulf-1 Modulates FGF2- and Hypoxia-Mediated Migration and Invasion of Breast Cancer Cells. Cancer Research. 71(6). 2152–2161. 46 indexed citations

Reinholz, Monica M., Kathleen Tenner, David W. Hillman, et al.. (2011). Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437. Clinical Cancer Research. 17(22). 7183–7193. 45 indexed citations

Simon, Vernadette, Richard M. Feddersen, Fariborz Rakhshan, et al.. (2011). Quantitative miRNA Expression Analysis Using Fluidigm Microfluidics Dynamic Arrays. BMC Genomics. 12(1). 144–144. 1 indexed citations

10.

Perez, Edith A., Monica M. Reinholz, David W. Hillman, et al.. (2010). HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology. 28(28). 4307–4315. 176 indexed citations

11.

Reinholz, Monica M., Jeanette E. Eckel‐Passow, S. Keith Anderson, et al.. (2010). Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL®platform. BMC Medical Genomics. 3(1). 60–60. 11 indexed citations

12.

Balan, Vitaly, Pratima Nangia‐Makker, Ann G. Schwartz, et al.. (2008). Racial Disparity in Breast Cancer and Functional Germ Line Mutation in Galectin-3 (rs4644): A Pilot Study. Cancer Research. 68(24). 10045–10050. 49 indexed citations

13.

Hartmann, Lynn C., Gary L. Keeney, Wilma L. Lingle, et al.. (2007). Folate receptor overexpression is associated with poor outcome in breast cancer. International Journal of Cancer. 121(5). 938–942. 197 indexed citations

14.

Narita, Keishi, Jeremy Chien, Sally A. Mullany, et al.. (2007). Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer. Journal of Biological Chemistry. 282(19). 14413–14420. 66 indexed citations

15.

Lingle, Wilma L., et al.. (2006). Deregulation of the Centrosome Cycle and the Origin of Chromosomal Instability in Cancer. Advances in experimental medicine and biology. 570. 393–421. 57 indexed citations

16.

Salisbury, Jeffrey L., Clark M. Whitehead, Wilma L. Lingle, & Susan L. Barrett. (1999). Centrosomes and cancer. Biology of the Cell. 91(6). 451–460. 73 indexed citations

17.

Newell, Steven Y., David Porter, & Wilma L. Lingle. (1996). Lignocellulolysis by ascomycetes (fungi) of a saltmarsh grass (smooth cordgrass). Microscopy Research and Technique. 33(1). 32–46. 42 indexed citations

18.

Porter, David & Wilma L. Lingle. (1992). Endolithic Thraustochytrid Marine Fungi from Planted Shell Fragments. Mycologia. 84(3). 289–299. 20 indexed citations

19.

O’Kane, Dennis J., Wilma L. Lingle, David Porter, & John E. Wampler. (1990). Localization of Bioluminescent Tissues During Basidiocarp Development in Panellus Stypticus. Mycologia. 82(5). 595–606. 12 indexed citations

20.

O’Kane, Dennis J., Wilma L. Lingle, David Porter, & John E. Wampler. (1990). Spectral Analysis of Bioluminescence of Panellus Stypticus. Mycologia. 82(5). 607–616. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact